Lung Cancer Market Size & Growth Forecast 2027–2036, By Segments (Diagnostics and Therapeutics, Indication, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Lung Cancer Market size was valued at USD 41.71 Billion in 2026 and is anticipated to grow at 11.02% CAGR from 2027 to 2036, exceeding USD 118.65 Billion by 2036. The industry revenue for 2027 is assessed at USD 45.69 Billion.

• Base Year Value (2026): USD 41.71 Billion
• CAGR (2027-2036): 11.02%
• Forecast Year Value (2036): USD 118.65 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Lung Cancer Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America led in 2025 due to advanced oncology infrastructure, broad diagnostic access, specialized treatment centers, and strong adoption of precision medicine.
  • Asia Pacific is growing fastest as healthcare infrastructure, cancer screening awareness, specialized centers, healthcare spending, and access to advanced oncology treatments expand.

• Segment Momentum:

  • Therapeutics accounted for 56.5% share in 2025 due to advancements in targeted therapies, immunotherapies, and combination treatments supporting personalized lung cancer management.
  • Specialty clinics are expanding fastest as demand rises for focused oncology services, personalized treatment plans, and convenient outpatient cancer care models.

• Market Expansion Drivers:

  • Rising global lung cancer prevalence driving demand for advanced oncology treatment solutions
  • Increasing adoption of targeted therapies and immuno-oncology drugs improving survival outcomes
  • Expanding low-dose CT screening programs enabling earlier lung cancer detection and intervention

• Leading Market Participants:

  Prominent companies in the lung cancer market include F. Hoffmann-La Roche AG (Switzerland), Bristol-Myers Squibb Company (United States), Merck & Co., Inc. (United States), Pfizer Inc. (United States), AstraZeneca plc (United Kingdom), Sanofi S.A. (France), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Biodesix Inc. (United States), CHEPLAPHARM Arzneimittel GmbH (Germany)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 41.71 Billion
  • 2027 Estimated Market Size: USD 45.69 Billion
  • Projected Market Size: USD 118.65 Billion by 2036
  • Growth Forecasts: 11.02% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Therapeutics (Diagnostics and Therapeutics) | Non-small Cell Lung Cancer (Indication) | Hospitals (End Use)
  • Emerging Opportunity Segment: Therapeutics (Diagnostics and Therapeutics) | Non-small Cell Lung Cancer (Indication) | Specialty Clinics (End Use)

Market Growth Drivers and Industry Trends

Rising global lung cancer prevalence driving demand for advanced oncology treatment solutions

The persistent burden of lung cancer is increasing the number of patients requiring diagnosis, treatment, and long-term disease management, which will drive the lung cancer market growth. A broad patient population creates sustained demand for therapeutic approaches spanning surgery, radiation, chemotherapy, targeted treatment, immunotherapy, and supportive care, depending on disease stage and biological characteristics. Greater clinical recognition of different lung cancer subtypes is also encouraging more individualized treatment strategies rather than relying on uniform therapeutic approaches. As healthcare systems expand oncology capacity and seek to improve outcomes across increasingly complex patient populations, demand for advanced treatment options continues across both newly diagnosed and previously treated patients.

Increasing adoption of targeted therapies and immuno-oncology drugs improving survival outcomes

The growing use of targeted treatments and immuno-oncology therapies is reshaping the lung cancer market by enabling treatment decisions to be increasingly aligned with tumor biology and immune response. Molecular testing can identify actionable alterations that allow eligible patients to receive therapies designed around specific cancer pathways, while immune-based treatments can activate or enhance the body's ability to recognize and attack malignant cells. These approaches are expanding treatment options for patients whose disease characteristics make them suitable for precision or immune-directed therapy and are also supporting more differentiated treatment sequences across disease stages. Continued advances in biomarker identification and therapeutic development are strengthening the role of personalized oncology in routine lung cancer care.

Expanding low-dose CT screening programs enabling earlier lung cancer detection and intervention

Broader implementation of low-dose computed tomography screening is improving opportunities to identify lung cancer at earlier stages, supporting the lung cancer market through greater detection and subsequent treatment needs. Screening programs can identify suspicious pulmonary abnormalities before symptoms become apparent, allowing clinicians to conduct follow-up diagnostic assessments and determine appropriate intervention pathways. Earlier identification can increase the proportion of patients evaluated while disease remains more amenable to curative or disease-controlling treatment, supporting demand across surgery, radiation, systemic therapies, and diagnostic services. As healthcare systems strengthen screening pathways for populations at elevated risk, integration between imaging, clinical assessment, biopsy, molecular testing, and treatment planning becomes increasingly important.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global lung cancer prevalence driving demand for advanced oncology treatment solutions	4.1%	High	North America, Europe, Asia Pacific	High	Near Term
Increasing adoption of targeted therapies and immuno-oncology drugs improving survival outcomes	3.7%	High	North America, Europe	High	Near Term
Expanding low-dose CT screening programs enabling earlier lung cancer detection and intervention	3.2%	High	North America, Europe, Asia Pacific	High	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest position in the lung cancer market in 2026, supported by advanced oncology infrastructure, widespread access to diagnostic services, and strong adoption of innovative cancer therapies. The region benefits from established screening and diagnostic capabilities that facilitate earlier identification and management of lung cancer, while the availability of specialized oncology centers supports complex treatment pathways. Growing emphasis on precision medicine is also contributing to regional demand, as molecular testing and biomarker-based approaches increasingly guide treatment selection. In addition, continued investment in cancer research, improvements in targeted and immunotherapy-based treatment approaches, and increasing awareness of lung cancer diagnosis are supporting market development. These factors collectively strengthen the region’s position in lung cancer care and treatment.

Asia Pacific is expected to register the fastest growth, driven by the rising burden of cancer, improving healthcare infrastructure, and increasing access to advanced oncology diagnosis and treatment. Growing urbanization and changing lifestyle patterns in several countries are contributing to greater attention toward lung health and cancer management. At the same time, healthcare systems are expanding their diagnostic and treatment capabilities, enabling broader adoption of modern oncology technologies. Increasing awareness of cancer screening, growing availability of specialized medical centers, and rising healthcare expenditure are further supporting demand for effective lung cancer therapies. The expansion of precision oncology and greater adoption of advanced treatment modalities are expected to create substantial opportunities for market growth across the region.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Diagnostics and Therapeutics Segment Analysis: Therapeutics (Largest & Fastest-Growing Segment)

The therapeutics segment accounted for 56.5% of the lung cancer market in 2026 while also representing the fastest-growing category. The segment's leading position is driven by continuous advancements in targeted therapies, immunotherapies, and combination treatment approaches that have expanded therapeutic options for patients. Increasing emphasis on personalized medicine, improved treatment accessibility, and ongoing clinical innovation have further strengthened the adoption of therapeutic interventions. As healthcare systems continue to prioritize effective disease management, demand for advanced lung cancer treatments remains strong.

Indication Segment Analysis: Non-small Cell Lung Cancer (Largest & Fastest-Growing Segment)

Holding the largest share of the lung cancer market, the non-small cell lung cancer segment represented 81.05% in 2026 and also remained the fastest-growing indication. Its dominance reflects the high prevalence of this disease subtype and the broad availability of treatment options tailored to its biological characteristics. Growing use of molecular diagnostics, earlier disease detection, and expanding access to precision medicine have contributed to improved patient management and increased utilization of specialized therapies. Continued research into targeted treatment strategies is expected to sustain the segment's strong position.

End Use Segment Analysis: Hospitals (Largest Segment) vs Specialty Clinics (Fastest-Growing Segment)

The hospital end-use segment held the largest share of the market at 62.11% in 2026. Hospitals remain the primary setting for comprehensive lung cancer diagnosis and treatment because they provide multidisciplinary care, advanced imaging technologies, surgical capabilities, and access to specialized oncology teams. Their ability to manage complex treatment pathways and deliver integrated patient care continues to support their leading market position.

In the lung cancer market, specialty clinics are emerging as the fastest-growing end-use segment. Increasing demand for focused oncology services, shorter waiting times, and personalized treatment plans has encouraged greater utilization of specialty clinics. These facilities offer dedicated expertise in cancer care while supporting outpatient treatment models that improve convenience and continuity of care, contributing to their expanding role in lung cancer management.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Diagnostics and Therapeutics	Diagnostics, Therapeutics	Therapeutics	Therapeutics
Indication	Non-small Cell Lung Cancer, Small Cell Lung Cancer	Non-small Cell Lung Cancer	Non-small Cell Lung Cancer
End Use	Hospitals, Diagnostic Laboratories, Specialty Clinics, Others	Hospitals	Specialty Clinics

Competitive Landscape and Market Positioning

Key companies in the lung cancer market:

1. F. Hoffmann-La Roche AG (Switzerland)
2. Bristol-Myers Squibb Company (United States)
3. Merck & Co., Inc. (United States)
4. Pfizer, Inc. (United States)
5. AstraZeneca plc (United Kingdom)
6. Sanofi S.A. (France)
7. Sun Pharmaceutical Industries Ltd. (India)
8. Teva Pharmaceutical Industries Ltd. (Israel)
9. Biodesix, Inc. (United States)
10. CHEPLAPHARM Arzneimittel GmbH (Germany)

The lung cancer market is undergoing a competitive transformation as treatment developers increasingly compete through precision approaches, targeted therapies, and integrated disease management strategies. Providers that can address specific patient profiles through improved diagnostic alignment and personalized treatment pathways are gaining strategic importance within oncology care. Competition is extending beyond individual therapies toward broader treatment ecosystems that combine detection, monitoring, and therapeutic decision support. As clinical priorities shift toward improved outcomes and reduced treatment burden, market participants are differentiating through innovation that enables more tailored approaches to disease management.

Industry Development/News

Company Name	Date	Key Development
GSK	Jun-26	GSK agreed to acquire Nuvalent for approximately $10.6 billion, strengthening its lung cancer portfolio and expanding its oncology pipeline through a strategic investment in targeted cancer therapeutics.
Coreline Soft	Jun-26	Coreline Soft partnered with Mint Medical following technical integration to advance AI-enabled lung cancer screening, supporting deployment within Germany's screening framework through computer-aided detection capabilities.
Johnson & Johnson	May-25	Johnson & Johnson launched the Rybrevant and Lazcluze combination therapy in Japan, marking its entry into the Japanese market with a chemotherapy-free treatment option for newly diagnosed patients with EGFR-mutated lung cancer.
AstraZeneca	Sep-24	The FDA approved Osimertinib (Tagrisso) for adult patients with locally advanced, unresectable stage III non-small cell lung cancer, broadening treatment availability and complementing existing therapies.
BioNTech	Aug-24	BioNTech initiated a global Phase I clinical trial of its mRNA-based lung cancer vaccine BNT116 across 34 research sites in seven countries, advancing development of a novel immunotherapy approach for lung cancer.
AstraZeneca	Aug-24	AstraZeneca received U.S. approval for Imfinzi in combination with chemotherapy for the treatment of adult patients with resectable early-stage non-small cell lung cancer.
Amgen	May-24	Amgen received U.S. Food and Drug Administration approval for IMDELLTRA for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression following platinum-based chemotherapy.
Maverix Medical	Mar-24	Maverix Medical acquired diagnostic developer Cirrus Bio to establish a new testing division focused on developing a multiomic platform spanning lung cancer screening and disease management.